Sustained Release Oral Formulation For Treatment Of Parkinsons Disease

Starting soon · Phase 1/Phase 2

Conditions studied: Healthy Volunteers

In brief

LD/CD (medications to treat Parkinson's disease) will be delivered using an assembly of nested sachets made of permeable material. The assembly is placed in the oral/buccal cavity (between cheek and gum of lower jaw) and delivers continuous release of CD and LD for both transmucosal and gastrointestinal absorption. The combination of CD/LD in the inner sachet varies from that in the outer sachet. This allows for sequential release of CD and then LD to mimic a CD pretreatment method which is known to increase LD absorption and prolong its half-life.

Key facts

Study ID

NCT07709741

Run by

University of Minnesota

People needed

32

Starts

2026-09-30

Expected to finish

2027-06-30

Last updated by the study team

2026-08-10

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Adult healthy male or female
• Age 18 to 65 years
• Willingness and ability to complete study procedures

You may not qualify if…

• medical conditions that require taking medications regularly.

Where it is running

• University of Minnesota — Minneapolis, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.